Pharmaguy's Insights Into Drug Industry News
186.1K views | +32 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

The Hawaiian Shirt is Back from Italy and Ready for the Next Pharmaguy Social Media Pioneer Award Recipient!

The Hawaiian Shirt is Back from Italy and Ready for the Next Pharmaguy Social Media Pioneer Award Recipient! | Pharmaguy's Insights Into Drug Industry News | Scoop.it

I just received the coveted Hawaiian shirt from Davide Bottalico and the Roche Italy Digital Academy Team, recipients of the Fourth Annual Pharmaguy Social Media Pioneer Award (see "Davide Bottalico and the Roche Digital Academy Team Receive the 4th Annual Pharmaguy Social Media Pioneer Award!").

I was a little afraid that Davide would get pizza on the shirt when I spotted an image on his Facebook page of him wearing it. But I see that it is in mint condition -- freshly dry-cleaned and wrapped in plastic! Thanks Davide for taking such good care of this revered  symbol of "standing out from the crowd."

The Award gives kudos and recognition to the pioneers within the pharma industry who have lead the way through the darkness that is pharmaceutical social media – even if the end result did not meet their expectations, failed miserably in terms of ROI, or was just a pilot campaign to test the waters. Campaigns come and go, but pioneers move on to new positions and continue to spread their influence far and wide. 

Learn more about ALL the past recipients of this Award here. I hope to give shirt to the next recipient(s) of the Award sometime in October, 2014.

Pharma Guy's insight:


Although I know a lot of pharma people who are social media pioneers (e.g, see my TOP 100 Pharma Twitter Pioneers list), I need help to discover the people who often work behind the curtain -- moderating discussions, writing blogs, managing the Twitter accounts, etc. -- and who are more or less invisible. With your help, I hope to peel back the curtain and tell the stories of these people.

Please, if you know someone who I should consider to receive this award -- or if you yourself feel you quality -- let mw know. Use this form.

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

UK's NHS Says Boehringer's Health Info is "clear, accurate, balanced, evidence-based, & current"

UK's NHS Says Boehringer's Health Info is "clear, accurate, balanced, evidence-based, & current" | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Germany-based Boehringer Ingelheim has become the first pharma company to be awarded The Information Standard (TIS) certification for the healthcare information it provides to patients, their families and carers.


The certification, which covers materials published in England, serves as a 'kite mark' for the standard of information provided by companies and organisations, acknowledging the content has undergone rigorous assessment by an independent authority.


Commissioned by NHS England and run by Capita, the TIS is intended to help people identify what health and care information is clear, accurate, balanced, evidence-based and up-to-date among the sea of content they have access to.

Pharma Guy's insight:


Wow! This sound pretty impressive. But if you read  on, you will learn that (1) companies have to apply for the TIS certification, and (2) it could be that no other pharma company bothered to apply.


Nevertheless, applying for the TIS requires some work to make sure the information is up to snuff. So, Boehringer has to be commended for that.


"The Information Standard is a certification programme for all organisationsproducing evidence-based health and care information for the public. Anyorganisation achieving The Information Standard has undergone a rigorous assessment to check that the information they produce is clear, accurate, balanced, evidence-based and up-to-date. " To learn more about TIS, click here.

more...
No comment yet.